Treatment for Hepatitis C Virus Infection in Adults: Comparative Effectiveness
Response of Patients With HCV Genotype 2 or 3 Infection According to Dosage of Dual Therapy
Five trials compared standard-dose pegylated interferon alfa-2b (1.5 mcg/kg/week) with lower doses (1.0 or 0.75 mcg/kg/week) in patients with hepatitis C virus (HCV) genotype 2 or 3 infection. Dual therapy with lower doses of pegylated interferon alfa-2b was associated with lower sustained virologic response (SVR) rates when compared with standard doses (pooled relative risk, 89; 95-percent confidence interval, 0.79 to 1.0). The strength of evidence for this finding was rated moderate.
Three trials of patients with genotype 2 or 3 infection who did not specifically have advanced fibrosis or cirrhosis found no clear difference in the likelihood of SVR between lower doses of ribavirin (a 400-mg or 800-mg flat dose or a 600-mg to 800-mg weight-based dose) versus higher doses (an 800-mg or 1,200-mg flat dose or an 800-mg to 1,400-mg weight-based dose). The strength of evidence for this finding was rated moderate.
Keywords: finding | outcome | hepatitis C | HCV | treatment | dual therapy | genotype | strength of evidence
- Chou R, Hartung D, Rahman B, et al. Treatment for Hepatitis C Virus Infection in Adults: A Comparative Effectiveness Review. Evidence Report No. 76 (Prepared by the Oregon Evidence-based Practice Center under Contract No. 290-2007-10057-I). Rockville, MD: Agency for Healthcare Research and Quality; August 2012. AHRQ Publication No. 12-EHC113-EF. Available at www.effectivehealthcare.ahrq.gov/hepctreatment.cfm.
Your slide tray is being processed.